Human papillomavirus type 16 E6, E7, and L2 proteins (HPV16 E6/E7/L2)

Human papillomavirus type 16 (HPV16) E6, E7, and L2 proteins represent a composite antigenic target primarily utilized in the development of therapeutic vaccines and immunotherapies for HPV-associated cancers. The E6 and E7 proteins are potent oncoproteins essential for malignant transformation; E6 targets the p53 tumor suppressor for proteasomal degradation, while E7 binds and inactivates the retinoblastoma protein (pRb), collectively disrupting cell cycle control and apoptosis (Source: PMID: 24008298). The L2 protein serves as the minor capsid protein and is vital for the viral life cycle, facilitating the escape of the viral genome from endosomes and its transport to the nucleus during initial infection (Source: PMID: 23536664). Therapeutic strategies targeting cells expressing these proteins, such as the TA-CIN fusion protein vaccine, are designed to induce high-frequency antigen-specific T-cell responses to eliminate infected or transformed cells (Source: PMID: 11544371). This multi-antigen approach aims to overcome the immune evasion strategies of HPV and provide a broader range of epitopes for immune recognition compared to single-protein targets. Clinical applications focus on treating cervical, anal, and oropharyngeal cancers, as well as high-grade intraepithelial neoplasias where these viral proteins are constitutively expressed.

Other names

HPV16 E6/E7/L2 antigensTA-CIN antigensHPV16 oncoproteins and minor capsid proteinHuman papillomavirus type 16 early and late proteins

Induction of antigen-specific CD4+ and CD8+ T-cell responses and neutralizing antibodies against HPV16-infected or transformed cells.